KlothovsRG3

Klotho is a single-pass transmembrane protein primarily expressed in the kidney, parathyroid gland, and choroid plexus, with a soluble form (s-Klotho) cleaved from the membrane and circulating systemically as an endocrine factor. It exists in three forms — alpha-Klotho (the most studied, anti-ageing form), beta-Klotho (which partners with FGF21), and gamma-Klotho — each with distinct receptor partnerships and tissue effects.

At the receptor level, alpha-Klotho is the obligate co-receptor for fibroblast growth factor 23 (FGF23), enabling FGF23 to bind and activate FGFR1 receptors in the kidney to regulate phosphate excretion. This makes Klotho a central node in mineral metabolism. Beyond this canonical role, soluble Klotho exerts numerous endocrine effects: it inhibits the IGF-1/insulin signalling pathway (a conserved longevity mechanism shared with caloric restriction), enhances expression of antioxidant enzymes via FoxO transcription factor activation, suppresses Wnt signalling (reducing stem cell exhaustion), inhibits TGF-beta signalling (preventing fibrosis), and blocks NF-kB and NLRP3 inflammasome activation (reducing inflammaging).

The ageing phenotype connection is striking: mice lacking Klotho develop multi-organ ageing — atherosclerosis, osteoporosis, skin atrophy, cognitive decline — within weeks of birth, while mice with elevated Klotho expression live up to 30% longer than controls. In humans, circulating Klotho levels decline with age, and lower levels associate with increased mortality and chronic disease risk in observational studies. Recombinant alpha-Klotho is in early clinical development as a potential therapy for chronic kidney disease, cognitive decline, and broader age-related diseases. The 2026 research wave around Klotho has positioned it as one of the most promising single-protein interventions in the longevity field, though no therapeutic Klotho product is yet approved for human use.

Ginsenoside Rg3 is a dammarane-type triterpene saponin found in Panax ginseng, with significantly higher concentrations in red (steamed) ginseng compared to white (dried) ginseng, as the steaming process converts other ginsenosides into Rg3 through sugar moiety deglycosylation. It exists as two stereoisomers: 20(S)-Rg3 and 20(R)-Rg3, which have overlapping but distinct biological activities.

Rg3's anti-inflammatory mechanism centers on inhibition of the NF-κB signaling pathway. It prevents phosphorylation and degradation of IκBα, keeping the NF-κB p65/p50 complex sequestered in the cytoplasm and blocking transcription of pro-inflammatory genes including TNF-α, IL-1β, IL-6, COX-2, and iNOS. This broad anti-inflammatory effect is complemented by modulation of the MAPK pathways (ERK, JNK, p38), further reducing inflammatory mediator production.

The anti-angiogenic and anti-tumor properties involve multiple mechanisms. Rg3 suppresses VEGF expression and VEGF receptor signaling (VEGFR2/KDR), inhibiting the formation of new blood vessels that tumors require for growth beyond a few millimeters (tumor angiogenesis). It modulates the PI3K/Akt/mTOR pathway — inhibiting Akt phosphorylation to reduce cell survival signaling and promote apoptosis in cancer cells. It enhances innate immune surveillance by increasing NK cell cytotoxic activity and promoting dendritic cell maturation and antigen presentation, improving the immune system's ability to detect and eliminate abnormal cells. Rg3 also inhibits epithelial-to-mesenchymal transition (EMT) — the process by which cancer cells acquire migratory and invasive properties for metastasis — by modulating TGF-β signaling and maintaining E-cadherin expression. The combination of anti-inflammatory, anti-angiogenic, pro-apoptotic, and immune-enhancing properties has led to Rg3's approval as a cancer adjunct therapy in China and South Korea, though it is not recognized as a drug in Western regulatory frameworks.